Lanreotide
A somatostatin analog with acromegaly, GEP-NET and carcinoid-syndrome indications.
FDA-approved product context
A somatostatin analog with acromegaly, GEP-NET and carcinoid-syndrome indications.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Evidence and source limits
The February 2025 lanreotide label identifies specific adult acromegaly, gastroenteropancreatic neuroendocrine tumor and carcinoid-syndrome uses. It is a healthcare-provider-administered deep subcutaneous product.
Warnings include gallstones, blood-glucose changes, cardiovascular and thyroid abnormalities, and fat malabsorption. These are disease-specific product indications, not anti-aging claims.
Approval applies to the specific labeled product, route and indication, not every preparation of this ingredient or a wellness mixture. Read the original full label and discuss individual circumstances with a medical professional. No dosing or preparation instructions are included.
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.